Výsledky vyhledávání

Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

Autor: C. Montagut, Joan Albanell, B Ferrer, E Campo, M. Suárez, Ana Rovira, P.L. Fernández, J M Corominas, Pedro Gascón, X Fabregat, B Bellosillo, S. Serrano, C Campas, Ignasi Tusquets

Publikováno v: Endocrine-Related Cancer. 13:607-616

The nuclear factor (NF)-kappaB system is a promising anticancer target due to its role in oncogenesis and chemoresistance in preclinical models. To provide evidence in a clinical setting on the role of NF-kappaB in breast cancer, we aimed to study th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2921256d42fb80674b16ffa148853d2b
https://doi.org/10.1677/erc.1.01171

Zobrazit plný text záznamu

A phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer

Autor: X Fabregat-Mayol, M Gallén-Castillo, M Nogué-Aliguer, E Saigı́-Grau, C Vadell-Nadal

Publikováno v: Lung Cancer. 28:109-115

Objective: This phase II trial was designed to assess the efficacy and toxicity profile of the combination of gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b632135313798978c88ab064240443f7
https://doi.org/10.1016/s0169-5002(99)00119-1

Zobrazit plný text záznamu

Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis

Autor: C. Vadell, A. Salvador, G. Pérez Manga, I. Bover, P. Viladiu, M.a.M. Barros, Victor Moreno, Xavier Garcia-del-Muro, X. Fabregat, M. Beltrán, J. Rifa, J.R. Germà

Publikováno v: European Journal of Cancer. 34:193-195

In a randomised, double-blind and parallel-design multicentre study, 282 chemotherapy-naive cancer patients received tropisetron 5 mg intravenously (i.v.) before high-dose cisplatin on day 1, and oral tropisetron 5 mg daily on days 2–6, in combinat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d64b437fc77445e7878a154aa2d2ea
https://doi.org/10.1016/s0959-8049(97)00367-5

Zobrazit plný text záznamu

[Acquired immunodeficiency syndrome and T-cell non-Hodgkin's lymphoma]

Autor: M, Doménech, I, Tusquets, X, Fabregat, C, Vadell, J M, Corominas, H, Knobel

Publikováno v: Medicina clinica. 99(6)

The clinical observation of a 40 years old male presenting acquired immune deficiency syndrome and T-cell non Hodgkin's lymphoma is presented. The patient was treated with COMET-A regimen (cyclophosphamide, vincristine, methotrexate, etoposide and cy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c6b78addb3a890d96351849db850f9d9
https://pubmed.ncbi.nlm.nih.gov/1507913

Zobrazit plný text záznamu

[Yield of diagnostic tests in neoplasms of unknown origin. A retrospective study]

Autor: M, Gil Gil, C, Vadell Nadal, X, Fabregat Mayol, I, Tusquets Trias de Bes, M, Nogué Aliguer

Publikováno v: Revista clinica espanola. 186(6)

A retrospective analysis of 54 patients diagnosed of neoplasia of unknown origin between January 1983 and December 1987 are presented. The patients's characteristics, histologic type, localization of metastasis, diagnostic procedures used and their c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::90610bfd388095f9e42ef9dbd3f7eaec
https://pubmed.ncbi.nlm.nih.gov/2118269

Zobrazit plný text záznamu

Phase II trial of temozolomide as first-line treatment for patients with advanced gynecological sarcoma: A Spanish Group for Research on Sarcomas (GEIS) and Spanish Ovarian Cancer Research Group (GEICO) study

Autor: Andres Poveda, Elena Galve Calvo, L. M. De Sande, J. M. Buesa, A. Lopez Pousa, Pilar Escudero, X. Fabregat, J. Martinez Trufero, X. Garcia del Muro, Antonio Casado

Publikováno v: Journal of Clinical Oncology. 24:9570-9570

9570 Background: Temozolomide (TMZ) as an extended schedule showed activity in the subgroup of patients (pts) with pretreated gynecological sarcoma (GS) in a prior phase II study (Cancer 2005;104:1706) as well as in a series of GS pts treated in a co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::79691a528e2be78c1f6621b666cd557a
https://doi.org/10.1200/jco.2006.24.18_suppl.9570

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání